NCT04145687

Metformin In Prevention of Lupus Nephritis

Metformin In Prevention Of Lupus Nephritis In High Risk Patients

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: RenJi Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Lupus nephritis (LN) is a main manifestation of systemic lupus erythematosus (SLE), which will largely effect the prognosis of SLE patients. Our previous 10-year data showed that the development of LN is most common in the first year of SLE, occupying about 17%. And our group has established a prediction model to predict the 1-year probability of LN for SLE patients without renal involvement. Our previous proof-of-concept trial and multicenter, randomized, double-blind, placebo-controlled trial indicated that metformin seemed to have potential to reduce the new-onset of LN in SLE patients (Unpublished data, in review). So the investigators tried to illustrate whether metformin has effect to prevent the development of lupus nephritis in high risk SLE patients based on LN prediction model.

Conditions

• Lupus Nephritis

Interventions

Type	Name	Description
DRUG	Metformin	Metformin 500mg tid

Timeline

• Start date: 2019-11-01
• Primary completion: 2021-06-01
• Completion: 2022-06-01
• First posted: 2019-10-31
• Last updated: 2019-10-31

Locations

1 site across 1 country: China